CA2214922A1
(en)
*
|
1996-09-27 |
1998-03-27 |
Eli Lilly And Company |
Benzothiophene compounds, compositions, and methods
|
US5886025A
(en)
*
|
1997-03-06 |
1999-03-23 |
Baylor University |
Anti-mitotic agents which inhibit tubulin polymerization
|
US5804592A
(en)
*
|
1997-05-30 |
1998-09-08 |
Unimed Pharmaceuticals, Inc. |
Method for improving disturbed behavior and elevating mood in humans
|
IL132784A
(en)
*
|
1997-05-07 |
2004-07-25 |
Unimed Pharmaceutical Inc |
Pharmaceutical compositions containing dronabinol
|
US5939429A
(en)
*
|
1997-09-30 |
1999-08-17 |
Virginia Commonwealth University |
Cardiovascular uses of cannabinoid compounds
|
DE69910373T2
(de)
*
|
1998-05-04 |
2004-04-01 |
The University Of Connecticut, Farmington |
Analgetische und immunomodulierende cannabinoiden
|
US6110963A
(en)
*
|
1998-05-12 |
2000-08-29 |
American Home Products Corporation |
Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
US6103708A
(en)
|
1998-05-12 |
2000-08-15 |
American Home Products Corporation |
Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
|
AU4072799A
(en)
|
1998-05-12 |
1999-12-13 |
American Home Products Corporation |
2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
|
US6221902B1
(en)
|
1998-05-12 |
2001-04-24 |
American Home Products Corporation |
Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
|
US6699896B1
(en)
|
1998-05-12 |
2004-03-02 |
Wyeth |
Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
|
US6232322B1
(en)
|
1998-05-12 |
2001-05-15 |
American Home Products Corporation |
Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
US6451827B2
(en)
|
1998-05-12 |
2002-09-17 |
Wyeth |
2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
|
US7897598B2
(en)
*
|
1998-06-09 |
2011-03-01 |
Alexandros Makriyannis |
Inhibitors of the anandamide transporter
|
US7589220B2
(en)
*
|
1998-06-09 |
2009-09-15 |
University Of Connecticut |
Inhibitors of the anandamide transporter
|
US7161016B1
(en)
|
1998-11-24 |
2007-01-09 |
University Of Connecticut |
Cannabimimetic lipid amides as useful medications
|
US7276613B1
(en)
|
1998-11-24 |
2007-10-02 |
University Of Connecticut |
Retro-anandamides, high affinity and stability cannabinoid receptor ligands
|
US7001926B2
(en)
*
|
2000-03-10 |
2006-02-21 |
Oxigene, Inc. |
Tubulin binding agents and corresponding prodrug constructs
|
US6566560B2
(en)
|
1999-03-22 |
2003-05-20 |
Immugen Pharmaceuticals, Inc. |
Resorcinolic compounds
|
HUP0203437A3
(en)
|
1999-03-22 |
2003-07-28 |
Immugen Pharmaceuticals Inc So |
Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
|
US6310081B1
(en)
|
1999-05-10 |
2001-10-30 |
American Home Products Corporation |
Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
|
US6645947B1
(en)
*
|
1999-05-20 |
2003-11-11 |
Chitogenics, Inc. |
Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
|
US6849656B1
(en)
|
1999-09-17 |
2005-02-01 |
Baylor University |
Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
|
WO2001019794A2
(en)
*
|
1999-09-17 |
2001-03-22 |
Baylor University |
Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
|
FR2799124B1
(fr)
*
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
MXPA02005103A
(es)
|
1999-10-18 |
2003-09-25 |
Alexipharma Inc |
Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
|
US6900236B1
(en)
|
1999-10-18 |
2005-05-31 |
University Of Connecticut |
Cannabimimetic indole derivatives
|
US7119108B1
(en)
*
|
1999-10-18 |
2006-10-10 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US7741365B2
(en)
*
|
1999-10-18 |
2010-06-22 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
US8084467B2
(en)
*
|
1999-10-18 |
2011-12-27 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
US6943266B1
(en)
|
1999-10-18 |
2005-09-13 |
University Of Connecticut |
Bicyclic cannabinoid agonists for the cannabinoid receptor
|
FR2804604B1
(fr)
*
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
US7091240B2
(en)
*
|
2000-03-10 |
2006-08-15 |
Oxigene, Inc. |
Tubulin binding ligands and corresponding prodrug constructs
|
EP1263763B1
(de)
|
2000-03-10 |
2007-07-25 |
Baylor University |
Tubulin bindende liganden
|
JP2003534298A
(ja)
*
|
2000-05-23 |
2003-11-18 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
咳の新規治療法
|
US20020137802A1
(en)
*
|
2000-09-28 |
2002-09-26 |
Travis Craig R. |
Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
|
US6541510B2
(en)
*
|
2000-09-28 |
2003-04-01 |
Immugen Pharmaceuticals, Inc. |
Antiviral methods and compounds
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
JP2004532185A
(ja)
*
|
2001-01-26 |
2004-10-21 |
ユニバーシティ オブ コネチカット |
新規なカンナビミメティックリガンド
|
DE60237431D1
(de)
|
2001-01-29 |
2010-10-07 |
Univ Connecticut |
Rezeptor-selektive cannabimimetische aminoalkylindole
|
US7067539B2
(en)
*
|
2001-02-08 |
2006-06-27 |
Schering Corporation |
Cannabinoid receptor ligands
|
CA2452881C
(en)
*
|
2001-07-13 |
2012-03-06 |
University Of Connecticut |
Novel bicyclic and tricyclic cannabinoids
|
WO2003015700A2
(en)
*
|
2001-08-15 |
2003-02-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Novel vasoconstrictor cannabinoid analogs
|
CA2464333C
(en)
*
|
2001-10-26 |
2011-07-26 |
University Of Connecticut |
Heteroindanes: a new class of potent cannabimimetic ligands
|
WO2003061699A1
(fr)
*
|
2001-12-27 |
2003-07-31 |
Japan Tobacco, Inc. |
Remedes pour affections allergiques
|
AU2003217961B2
(en)
|
2002-03-08 |
2008-02-28 |
Signal Pharmaceuticals, Llc |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
CN1652766A
(zh)
*
|
2002-03-18 |
2005-08-10 |
免疫力药品有限公司 |
间苯二酚和***素的局部制剂及其施用方法
|
US6825209B2
(en)
*
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
MXPA04012704A
(es)
|
2002-06-19 |
2005-03-23 |
Schering Corp |
Agonistas de los receptores canabinoides.
|
NZ537003A
(en)
|
2002-07-18 |
2008-03-28 |
Cytos Biotechnology Ag |
Hapten-carrier conjugates comprising virus like particles and uses thereof
|
WO2004013120A1
(en)
*
|
2002-07-29 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Novel benzodioxoles
|
JP4667867B2
(ja)
*
|
2002-08-02 |
2011-04-13 |
メルク・シャープ・エンド・ドーム・コーポレイション |
置換フロ[2,3−b]ピリジン誘導体
|
US7183313B2
(en)
|
2002-08-23 |
2007-02-27 |
University Of Connecticut |
Keto cannabinoids with therapeutic indications
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
CA2502511A1
(en)
*
|
2002-10-18 |
2004-05-29 |
Pfizer Products Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
PL378244A1
(pl)
*
|
2003-01-02 |
2006-03-20 |
F. Hoffmann-La Roche Ag |
Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1
|
ES2334565T3
(es)
|
2003-01-02 |
2010-03-12 |
Hoffmann La Roche |
Agonistas inversos del receptor cb 1.
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
TW200505902A
(en)
*
|
2003-03-20 |
2005-02-16 |
Schering Corp |
Cannabinoid receptor ligands
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
*
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
MXPA05011922A
(es)
*
|
2003-05-07 |
2006-02-17 |
Pfizer Prod Inc |
Ligandos del receptor de cannabinoides y sus usos.
|
CN1809552A
(zh)
*
|
2003-05-20 |
2006-07-26 |
田纳西大学研究基金会 |
***素衍生物、其制备方法和用途
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
BRPI0411699A
(pt)
*
|
2003-06-20 |
2006-08-29 |
Hoffmannn La Roche Ag F |
compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
|
SI1637527T1
(sl)
|
2003-06-26 |
2013-07-31 |
Takeda Pharmaceutical Company Limited |
Modulator kanabinoidnega receptorja
|
US20050095674A1
(en)
*
|
2003-07-23 |
2005-05-05 |
Lewis Deborah L. |
Cannabinoid receptor interacting proteins and methods of use
|
WO2005023232A2
(en)
*
|
2003-09-04 |
2005-03-17 |
Affibody Ab |
Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
|
JP4598387B2
(ja)
*
|
2003-09-17 |
2010-12-15 |
株式会社日立製作所 |
記憶システム
|
KR100773650B1
(ko)
*
|
2003-12-08 |
2007-11-05 |
에프. 호프만-라 로슈 아게 |
신규한 싸이아졸 유도체
|
KR100843023B1
(ko)
*
|
2004-01-28 |
2008-07-01 |
에프. 호프만-라 로슈 아게 |
스피로-5환 화합물
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
EP1574211A1
(de)
|
2004-03-09 |
2005-09-14 |
Inserm |
Verwendung von CB1-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankungen
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US7456214B2
(en)
*
|
2004-05-03 |
2008-11-25 |
Baylor University |
Chromene-containing compounds with anti-tubulin and vascular targeting activity
|
US20050245489A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Pinney Kevin G |
Chromene-containing compounds with anti-tubulin and vascular targeting activity
|
KR100870346B1
(ko)
*
|
2004-05-10 |
2008-11-25 |
에프. 호프만-라 로슈 아게 |
비만 치료용 피롤 또는 이미다졸 아마이드
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2006039334A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
BRPI0517369A
(pt)
*
|
2004-10-27 |
2008-10-07 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
|
EP2286837A3
(de)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Behandlung von Fettleibigkeit und von verwandten Krankheiten
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
RU2391337C2
(ru)
*
|
2004-11-09 |
2010-06-10 |
Ф.Хоффманн-Ля Рош Аг |
Производные дибензосуберона
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
CA2602787C
(en)
*
|
2005-04-06 |
2013-12-24 |
F. Hoffmann-La Roche Ag |
Pyridine-3-carboxamide derivatives as cb1 inverse agonists
|
WO2006129193A2
(en)
*
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
KR100970055B1
(ko)
*
|
2005-06-22 |
2010-07-16 |
에프. 호프만-라 로슈 아게 |
6-(플루오로-벤조[1,3]디옥솔일)-모폴린-4-일-메탄온 및cb1 리간드로서 그의 용도
|
CA2617654A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Pfizer Limited |
Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
|
CA2518579A1
(en)
*
|
2005-08-05 |
2007-02-05 |
University Technologies International Inc. |
Method for appetite suppression
|
EP2330125A3
(de)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybridpolypeptide mit auswählbaren Eigenschaften
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US8138188B2
(en)
*
|
2006-02-23 |
2012-03-20 |
Pfizer Inc. |
Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
|
US7629346B2
(en)
*
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7781593B2
(en)
*
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
CA2669311C
(en)
|
2006-11-13 |
2011-09-20 |
Pfizer Products Inc. |
Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
PE20090142A1
(es)
*
|
2007-04-11 |
2009-02-19 |
Merck & Co Inc |
Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
|
CA2705708A1
(en)
*
|
2007-11-14 |
2009-05-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
US9623000B2
(en)
|
2008-07-31 |
2017-04-18 |
Dekel Pharmaceuticals Ltd |
Compositions and methods for treating inflammatory disorders
|
CA2731897C
(en)
*
|
2008-08-06 |
2013-07-02 |
Pfizer Limited |
Diazepine and diazocane compounds as mc4 agonists
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
FR2978660B1
(fr)
*
|
2011-08-05 |
2013-09-20 |
Oreal |
Utilisation d'antagoniste du recepteur cb1 en tant qu'agent blanchissant et/ou anti-brunissement des matieres keratiniques
|
EP2911660B1
(de)
*
|
2012-10-24 |
2019-12-04 |
The Board of Trustees of the University of Illionis |
Zusammensetzungen und verfahren zur behandlung östrogenvermittelter erkrankungen
|
WO2016011451A1
(en)
*
|
2014-07-18 |
2016-01-21 |
Medipath, Inc. |
Compositions and methods for physiological delivery using cannabidiol
|